PDL Preferred Drug List

The District of Columbia’s Health Care Finance Agency is forecasting a supplemental drug list initiative under the PDL Preferred Drug List framework, with a posted date of July 23, 2026. This action is part of the agency’s ongoing effort to manage pharmaceutical costs and ensure appropriate medication access for beneficiaries within the district’s health programs. Although the solicitation number and other standard procurement details are not yet provided, the forecast indicates a future procurement opportunity for pharmacies, manufacturers, or pharmacy benefit managers to submit drug listings or pricing proposals aligned with the agency’s formulary standards. The contract will likely involve evaluating drugs for inclusion or exclusion from the preferred drug list based on clinical effectiveness, cost-effectiveness, and therapeutic alternatives. The place of performance and point of contact information have not been specified, suggesting this is an early-stage forecast not yet ready for formal bids or proposals. Interested parties should monitor the official portal at the provided UI link for updates, as the final request for proposals or similar document will likely follow and require detailed submissions on drug pricing, formulary compliance, and adherence to district-specific coverage guidelines.